


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) An anti-estrogenic compound of the general formula I



I

wherein

A is a 8-22 atoms long substituent, ~~which wherein~~ substituent A is defined by comprises D<sub>1-6</sub>, wherein D is chosen from the group ~~comprising~~ consisting of R<sub>4</sub>-C(O)R<sub>4</sub>, R<sub>4</sub>S(O)<sub>0-2</sub>R<sub>4</sub>, N(R<sub>4</sub>)<sub>3</sub>, R<sub>4</sub>OR<sub>4</sub> and ~~R<sub>4</sub>(C<sub>6</sub>H<sub>4</sub>)R<sub>4</sub>~~ R<sub>4</sub>(C<sub>6</sub>H<sub>4</sub>)R<sub>4</sub>;

wherein R<sub>4</sub> independently represents a bond, ~~or~~ H, or a halogenated or non-halogenated, saturated or unsaturated, mono-, di-, or trivalent C<sub>1</sub>-C<sub>12</sub> ~~hydrocarbon~~ hydrocarbon;

B', B'' are H, H<sub>2</sub>, ~~or~~ H, O-R<sub>3</sub>, ~~or~~ O-R<sub>3</sub>, H<sub>2</sub>, ~~or~~ H, F<sub>1</sub>, or together represent =O;

R<sub>1</sub> is H, or a potentially metabolically unstable group chosen from the group ~~comprising~~ consisting of a straight, branched, or cyclic C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> acyl, benzoyl, sulphamoyl, ~~or~~ and N-acetyl-sulphamoyl;

R2 is H, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl or benzoyl;


R3 is H, ~~or~~ C1-C3 alkyl, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl; and

X is methylene or a single bond, or

pharmaceutically acceptable salts of the compounds of the general formula I.

2. (Currently amended) A compound according to claim 1,

wherein A is




3. (Currently amended) A compound according to ~~any of claims 1-2~~ claim 1,

wherein A is



4. (Currently amended) A compound according to ~~any of claims 1-2~~ claim 1,

wherein A is



wherein Y is chosen from H or F.


5. (Currently amended) A compound according to any of claims 1-4, wherein R1 is

hydrogen, ~~or~~ methyl, ~~or~~ acetyl, ~~or~~ benzoyl, ~~or~~ sulphamoyl, or N-acetyl-sulphamoyl.

6. (Currently amended) A compound according to ~~any of claims 1-5~~ any of claims 1-4,

wherein R3 is H, ~~or~~ methyl, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl.


7. (Currently amended) A compound according to claim 1,  
wherein A is



or



or




wherein Y is chosen from H or F or F,

or



or



or




R1 is hydrogen, or methyl, or acetyl, or benzoyl, or sulphamoyl, or N-acetyl-sulphamoyl;


R2 is hydrogen; and

R3 is H, or methyl, or a potentially metabolically unstable group chosen from the group  
comprising consisting of C1-C6 acyl, benzoyl, sulphamoyl, or and N-acetyl-sulphamoyl.


8. (Currently amended) A compound according to claim 1,  
wherein A is



or




or



wherein Y is chosen from H or F or F,

or




B',B" are H,H<sub>i</sub>; ~~or~~ H,O-R<sub>3</sub>; ~~or~~ O-R<sub>3</sub>,H<sub>i</sub>; or H,F;


R1 is H, ~~or~~ methyl, ~~or~~ acetyl, or sulphamoyl; and

R3 is H, ~~or~~ methyl, or acyl;


9. (Currently amended) A compound according to ~~claims~~ claim 1, wherein A is



~~or~~



or



and

R3 is H.

10. (Currently amended) A compound according to ~~any one of claims 1-9~~ claim 1 chosen from the group ~~comprising~~ consisting of:

11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,

11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate,

11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-acetate,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-benzoate,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]octyl]-estra-1,3,5(10)-triene,

7 $\alpha$ -[9-[(2,2,3,3,4,4,4-Heptafluoro-n-butyl)sulfinyl]nonyl]-3,16 $\alpha$ -dihydroxy-17-methylene-estra-1,3,5(10)-triene,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-benzoate,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,

10-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid methylester,

2-[9-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,

11-(3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,

3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11-(3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,

10-(3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

11-(6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,

6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,



6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11-(6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,

10-(6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11-(3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,

11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate,

11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-acetate,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]octyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-7 $\alpha$ -[9-[(2,2,3,3,4,4,4-heptafluoro-n-butyl)sulfinyl]nonyl]-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9[(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-benzoate,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-acetate,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,

10-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid methylester,

2-[9-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,

11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,

11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,

17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-7 $\alpha$ -[9-[(2,2,3,3,4,4,4-heptafluoro-n-butyl)sulfinyl]nonyl]-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

10-(17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid methylester,

11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid methylester,

2-[9-(17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,

11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,

11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,

17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid methylester,

17-(1,2-Ethylene)-3,6 $\beta$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 $\beta$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 $\beta$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 $\beta$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11-(17-(1,2-Ethylene)-3,6 $\beta$ ,16 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-3,6 $\beta$ ,16 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,



17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,


17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\alpha$ -methoxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\alpha$ -methoxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\beta$ -methoxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene, and

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\beta$ -methoxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene.

11. (Currently amended) An intermediate compound of the general formula VIII:



(VIII)

wherein ~~R1, R2 and X are as defined in claim 1~~

R1 is H, or a potentially metabolically unstable group chosen from the group consisting of a straight, branched, or cyclic C1-C6 alkyl, C1-C6 acyl, benzoyl, sulphamoyl, and N-acetyl-sulphamoyl;

R2 is H, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl or benzoyl; and

X is methylene or a single bond.

12. (Currently amended) A compound according to ~~any one of claims 1-10~~ claim 1 for use as a medicament.

13. (Currently amended) Use of a compound according to ~~any one of claims 1-10~~ claim 1 for the manufacturing of a medicament for the treatment of an estrogen related disorder or condition that benefits from antiestrogen treatment.

14. (Currently amended) Use according to claim 13, wherein the estrogen related disorder or condition is chosen from the group ~~comprising~~ consisting of estrogen dependent breast cancer, anovulatory infertility, menstrual disorders, male pattern baldness, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, uterine leiomyomas, adenomyosis, ovarian cancer, endometrial cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, endometriosis, polycystic ovary syndrome, infertility and contraception in males.

15. (Original) Use according to claim 13 or 14, wherein the estrogen related disorder is estrogen dependent breast cancer.

16. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1-10~~ claim 1, admixed with one or more pharmaceutically acceptable excipients or carriers.

17. (Original) A pharmaceutical composition according to claim 16, wherein the excipients are chosen from the group comprising filling agents, lubricants, flavours, colourings, sweetenings, buffers, acidifying agents, diluents and preservatives.
18. (Currently amended) A pharmaceutical composition according to any one of claims 16-17, for administration orally, intramuscularly, intravenously, intraperitoneally or subcutaneously, via implants, rectally, intranasally, transdermally, or ~~vaginally; preferably orally, transdermally or intranasally.~~ vaginally.
19. (Currently amended) A method of treatment comprising administration of a pharmaceutically effective amount of compound according to ~~claim 1-10-~~ claim 1 or a pharmaceutical composition according to ~~claim 16-17~~ claim 16 to a subject suffering from an estrogen dependent disorder or condition.
20. (Original) A method of treatment according to claim 19, wherein the estrogen dependent disorder or condition is chosen from the group comprising estrogen dependent breast cancer, anovulatory infertility, menstrual disorders, male pattern baldness, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, uterine leiomyomas, adenomyosis, ovarian cancer, endometrial cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, endometriosis, polycystic ovary syndrome, infertility and contraception in males.
21. (Currently amended) A method of treatment according to ~~claim 19 or 20~~ claim 19, wherein the estrogen dependent disorder is estrogen dependent breast cancer.